ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD.

Zhejiang Jingxin Pharmaceutical Co., Ltd.

002020

CNE000001K73

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
12.07 ^CNY	-0.82%		+1.77%	-5.11%

04-23	Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-01	Zhejiang Jingxin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI

Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022

April 24, 2023 at 03:48 pm

Zhejiang Jingxin Pharmaceutical Co., Ltd. at its AGMM held on April 21, 2023 approved final cash dividend/10 shares (tax included) of CNY 3.00000000 for the year 2022.

Latest news about Zhejiang Jingxin Pharmaceutical Co., Ltd.

Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	04-01	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Evotec Says Partner Obtained Regulatory Approval in China for Insomnia Drug	12-06	MT
Jingxin Pharmaceutical Gets Nod to Market Didacinil Capsules	12-06	MT
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Jingxin Pharma's Unit Gets Nod to Market Eye Drug in Europe	23-06-13	MT
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan, Payable on 24 May 2023	23-05-18	CI
ExoRNA Bio announced that it has received funding from Guangzhou Yuexiu Industrial Investment Fund Management Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., Dingxin Capital Co., Ltd., CDH Investment Management Company Limited and other investors	23-05-14	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022	23-04-24	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-03-30	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments	22-10-14	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 25 May 2022	22-05-18	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves 2021 Profit Distribution Plan At the Annual General Meeting Held on April 22, 2022	22-04-25	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces the Final Profit Distribution Proposal for 2021	22-03-30	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. signed an agreement to acquire Guangdong Shaxi Pharmaceutical Co., Ltd. from Jingxin Holding Group Co., Ltd. and Xinchang Yuanjin Health Industry Investment Partnership Enterprise (Limited Partnership) for approximately CNY 210 million.	21-11-08	CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Zhejiang Jingxin Pharmaceutical : Pharma Chairman Raises Stake to 35% in $77 Million Deal	21-09-09	MT

Chart Zhejiang Jingxin Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Jingxin Pharmaceutical Co., Ltd.

More charts

ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. is a China-based company engaged in manufacture of pharmaceuticals. The Company's pharmaceutical products include chemical pharmaceuticals, traditional medicines, biological agents and bulk pharmaceutical chemicals. Its pharmaceutical products are mainly applied in cardiovascular sector, digestive tract sector and psychoneural sector, among others. The Company is also engaged in the research and development, manufacture and sales of medical devices. Its medical devices include clinical displays, diagnosis displays, endoscopic surgery displays and ultrasonic image displays, among others. The Company operates its businesses in both domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Jingxin Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.07

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD.	-5.11%	1.44B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals